바이오테크 보도자료
-
- Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (Ch...
- 2020년 12월 21일
-
- New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
- Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizin...
- 2020년 12월 21일
-
- Kaye Introduces the Kaye® Log -80 Vaccine Temperature Logger for Cold Chain Market to Address COVID-19 Vaccine Storage and Transportation Requirements
- Kaye has been a leader for over 60 years in the Validation and Monitoring of critical process data. With its introduction of the Kaye Log -80 Vaccine Temperature Logger and KayeTrack Cloud Kaye has applied the same quality principles to ensure the...
- 2020년 12월 18일
-
- rf IDEAS and Nymi Partner for Truly Contactless Authentication Solutions
- rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, announced a new technology partnership with Nymi, the creator of the Nymi Band™, an innovative workplace wearable wristband for secure hands-free authent...
- 2020년 12월 16일
-
- Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
- Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline quality management on a single cloud platform. The add...
- 2020년 12월 15일
-
- Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
- As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for th...
- 2020년 12월 11일
-
- Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
- Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies...
- 2020년 12월 11일
-
- GLEIF Advances Digital Trust and Identity for Legal Entities Globally
- The Global Legal Entity Identifier Foundation (GLEIF) is to extend the Global LEI System to create a fully digitized LEI service capable of enabling instant and automated identity verification between counterparties operating across all industry s...
- 2020년 12월 11일
-
- Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition that underscore its commitm...
- 2020년 12월 10일
-
- PMC Organometallix Continues Expansion
- PMC Organometallix Inc., a wholly owned subsidiary of PMC Group N.A., Inc. is pleased to confirm that, despite challenges presented by the global pandemic, it has embarked on, and will continue with plans to expand capacity for production of organ...
- 2020년 12월 10일
전시회
